Department of Neurosurgery, Helios Universitätsklinikum Wuppertal, Universität Witten/Herdecke, Heusnerstr. 40, 42283, Wuppertal, Germany.
Department of Stereotaxy and Functional Neurosurgery, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.
Acta Neurochir (Wien). 2023 Apr;165(4):967-973. doi: 10.1007/s00701-022-05448-8. Epub 2023 Jan 4.
Spinal cord stimulation (SCS) is a therapeutic option for patients with a peripheral arterial disease with critical limb ischemia (CLI) and consequent ischemic rest pain. Neuromodulation is chosen when vascular reconstruction is not possible or failed. Data about the effect of SCS over limb salvage rates are dissonant.
We report on a retrospective cohort of CLI patients who were implanted with SCS systems between July 2010 and December 2013 in a single center. Major amputation, postoperative complications, and death were recorded.
Seventy-two CLI patients underwent SCS implantation, with 35 of them classified as non-reconstructable and 37 with previous but failed or only partially successful vascular procedures. A total of 21 subjects were at Fontaine's stage III (29.2%), and the remaining 51 were at stage IV (70.8%). In total, 26.4% of the patients had diabetes (n = 19), two of them at Fontaine's stage III. The mean follow-up was 17.1 ± 10.5 months. At the last follow-up, 59.2% of all patients (42/71), 85.7% of Fontaine's stage III (18/21), 48.0% of Fontaine's stage IV (24/50), and 52.6% of diabetic patients (10/19) were alive without major amputation. The probability of limb survival at 12 months was 72% for all patients, 94% for Fontaine's stage III, 62% for Fontaine's stage IV, and 61% for diabetic patients. The probability of survival at 12 months for patients who underwent major limb amputation (n = 25) was 86% with a mean survival time of 31.03 ± 4.63 months.
Non-reconstructable CLI patients treated with SCS can achieve meaningful clinical outcomes with few procedure-related complications. The therapy may be more beneficial in patients classified as Fontaine's Stage III.
脊髓刺激(SCS)是伴有严重肢体缺血(CLI)和随之而来的缺血性静息痛的外周动脉疾病患者的一种治疗选择。当血管重建不可行或失败时,选择神经调节。关于 SCS 对肢体存活率影响的数据存在差异。
我们报告了 2010 年 7 月至 2013 年 12 月在一家单中心接受 SCS 系统植入的 CLI 患者的回顾性队列。记录主要截肢、术后并发症和死亡。
72 例 CLI 患者接受了 SCS 植入,其中 35 例为不可重建,37 例为既往血管手术失败或仅部分成功。共有 21 名患者处于 Fontaine Ⅲ期(29.2%),其余 51 名患者处于Ⅳ期(70.8%)。共有 26.4%的患者(n=19)患有糖尿病,其中 2 例为 Fontaine Ⅲ期。平均随访时间为 17.1±10.5 个月。在最后一次随访时,71 例患者中有 59.2%(42/71)、21 例 Fontaine Ⅲ期患者中有 85.7%(18/21)、50 例 Fontaine Ⅳ期患者中有 48.0%(24/50)和 19 例糖尿病患者中有 52.6%(10/19)存活且无主要截肢。所有患者 12 个月肢体存活率为 72%,Fontaine Ⅲ期为 94%,Fontaine Ⅳ期为 62%,糖尿病患者为 61%。接受主要肢体截肢(n=25)的患者 12 个月的存活率为 86%,平均生存时间为 31.03±4.63 个月。
接受 SCS 治疗的不可重建的 CLI 患者可以获得有意义的临床结果,且很少出现与手术相关的并发症。该疗法可能对 Fontaine Ⅲ期患者更有益。